

Case study

Use of Tedizolid for the Treatment of *Staphylococcus aureus*

Bacteremia – an off labelled indication

Abstract

Aims

We aim to share our experience in the successful use of tedizolid for the treatment of ~~staphylococcus~~ *Staphylococcus aureus* bacteremia in two of our patients.

Comment [u1]: *Staphylococcus aureus* Change in all the text

Presentation of cases

Our first patient has methicillin-resistant *staphylococcus aureus* (MRSA) bacteremia. The MRSA isolated was sensitive to linezolid and vancomycin (MIC=2), resistant to daptomycin (MIC=2). In view of documented drug allergy to ceftriaxone and drug interaction with daptomycin, patient was initially initiated on intravenous vancomycin but developed breakthrough fever with rising inflammatory markers. However, upon initiation of tedizolid, fever lysed and patient improved clinically.

Our second patient has end stage renal failure on hemodialysis. Patient has methicillin-susceptible *staphylococcus aureus* (MSSA) catheter-related bloodstream infection. The MSSA isolated was sensitive to vancomycin (MIC=2) and ceftaroline (MIC=0.50), but resistant to daptomycin (MIC=2). Vancomycin was initiated in view of documented drug allergy to ceftriaxone but repeated blood cultures showed persistence of MSSA. Antibiotics were switched to linezolid for 3 days before switching to tedizolid due to previous neutropenia with linezolid. Blood cultures had documented clearance with tedizolid.

23 **Discussion and conclusion**

24 In both our patients, tedizolid was introduced after few days of vancomycin therapy. Hence,
25 efficacy of tedizolid as the first-line therapy for treatment of staphylococcus bacteremia remains
26 unknown. Nevertheless, in both patients, there was no relapse of staphylococcus bacteremia and
27 infections when tedizolid was used to complete the antibiotic therapy. The optimal treatment
28 duration of staphylococcus bacteremia with tedizolid also remains unknown.

29
30 **Introduction**

31
32 For decades, vancomycin has been the cornerstone for treatment of methicillin-resistant
33 *staphylococcus aureus* (MRSA) infections, but increasingly, creeping minimum inhibitory
34 concentration (MIC) of MRSA has resulted in treatment failure [1]. In view of the lack of
35 clinical experience in the use of tedizolid for off-labelled indications, we describe two patients
36 with MRSA/MSSA bacteremia and were treated with tedizolid successfully.

37
38 **Case Presentation**

39 The first patient was a 51-year-old Chinese male. His medical history was significant for
40 diabetes mellitus, depression and alcohol dependency with Child's B alcoholic liver cirrhosis. He
41 presented with giddiness and was febrile (37.7°C) on admission. He was recently admitted for
42 mild pancreatitis, was given ceftriaxone but developed fixed drug eruption (diagnosed by
43 dermatologist). MRSA screen came back positive and blood cultures subsequently grew MRSA
44 – sensitive to linezolid and vancomycin (MIC=2), resistant to daptomycin (MIC=2). Heart echo
45 revealed no vegetation.

46

47 Despite the high MIC, patient was initiated on vancomycin due to limited therapeutic options –
48 loading dose of 20mg/kg, followed by 20mg/kg Q12h. Despite receiving high doses of
49 vancomycin (25mg/kg Q12h) after several titrations, serum vancomycin troughs remained
50 persistently sub-therapeutic (4.4 – 13mg/L). Patient’s renal function remained good throughout
51 with no change in urine output. Blood cultures were negative on day 3 of vancomycin but on day
52 13 of vancomycin therapy, patient spiked fever (39.9°C) and repeated inflammatory markers
53 (pro-calcitonin, C-reactive protein and white cell count) were up-trending. As patient was
54 taking escitalopram for depression, concurrent use with linezolid was not recommended due to
55 risk of serotonin syndrome. Ceftaroline was contraindicated as patient is allergic to ceftriaxone.
56 In light of poor response to vancomycin with breakthrough fever and limited therapeutic options,
57 intravenous tedizolid 200mg once-daily was initiated. Thereafter, fever normalized and
58 inflammatory markers were down-trending. Repeated blood cultures remained negative, patient
59 completed one week of tedizolid, was discharged well without antibiotics and there was no
60 relapse of infection on follow up.

61

62 Our second patient was a 58-year-old Chinese male who presented with fever (39°C), chills and
63 rigors. Patient had end-stage renal failure; on thrice-weekly hemodialysis since 2010. Due to
64 recurrent vascular access issues, patient had been dialyzing through permanent catheters. He was
65 recently admitted and given 1 week of intravenous vancomycin for catheter exit-site infection,
66 and blood cultures were negative then. In this current admission, blood cultures sent on
67 admission grew MSSA – sensitive to vancomycin (MIC=2), ceftaroline (MIC=0.50), resistant to
68 daptomycin (MIC=2). Heart echo revealed no vegetation. Vancomycin was initiated as patient

Comment [u2]: vancomycin

69 had type I hypersensitivity reaction to ceftriaxone. Infected permanent catheter was removed on
70 day 2 of admission but repeated blood cultures showed persistence of MSSA up to day 6 of
71 admission (two sets of blood cultures were repeated on a daily basis). Hence, in view of
72 treatment failure with vancomycin and patient's drug allergy, linezolid was initiated but was later
73 switched to tedizolid 200mg once-daily after 3 days – taking into account patient's previous
74 history of known thrombocytopenia with linezolid. On the day of switch from linezolid to
75 tedizolid therapy, repeat blood cultures came back negative. While using tedizolid, patient's
76 platelet count was monitored closely. Platelet counts were normal initially and patient was
77 planned for 2-weeks course of tedizolid. However, on day 11 of tedizolid therapy, platelet count
78 dropped to $<100 \times 10^9/L$ and tedizolid was stopped. Patient was subsequently discharged well
79 without antibiotics. Two weeks post-discharge, patient's platelet counts normalized and there
80 was no relapse of infections.

81

82 **Discussion**

83 In both our patients, alternative anti-MRSA/anti-MSSA therapies (daptomycin, ceftaroline,
84 linezolid) within our formulary were taken into consideration in view of therapeutic failure with
85 vancomycin. Both our patients had severe allergic reactions to ceftriaxone and this prohibits the
86 use of ceftaroline. Daptomycin could not be used both of MSSA/MRSA from our patients
87 exhibit a high MIC of 2 to daptomycin (resistant). Linezolid was not used or continued in view
88 of drug interactions and adverse drug effects observed.

89

90 Multiple studies have demonstrated tedizolid's potent in-vitro activity against MSSA/MRSA [2].

91 Tedizolid's long elimination half-life (10-12h) and its improved potency allows for a lower dose

92 to be used. This contributes to a lower incidence of thrombocytopenia, when compared to
93 linezolid [3]. In addition, tedizolid does not appear to have significant drug interaction with
94 serotonergic agents [4].

95

96 In both our patients, tedizolid was introduced after few days of vancomycin therapy. Hence,
97 efficacy of tedizolid as the first-line therapy for treatment of staphylococcus bacteremia remains
98 unknown. Nevertheless, in both patients, there was no relapse of staphylococcus bacteremia and
99 infections when tedizolid was used to complete the antibiotic therapy. The optimal treatment
100 duration of staphylococcus bacteremia with tedizolid also remains unknown.

101

102 **Conclusion**

103 To date, tedizolid is only licensed for the treatment of ABSSSI, with investigational use in
104 nosocomial pneumonia. While evidence for its use in bacteremia is lacking, we reported that
105 tedizolid is effective and safe in the treatment of *staphylococcus aureus* bacteremia, with no
106 relapse.

107

108 **Declarations**

109 **Funding:** No funding

110 **Competing Interests:** The authors report no conflict of interests. The authors alone are
111 responsible for the content and writing of the paper.

112 **Ethical Approval:** Not required

113

114

115 **References**

- 116 [1] Rybak JM, Roberts K. Tedizolid Phosphate: a Next-Generation Oxazolidinone. *Infect Dis*
117 *Ther* 2015 (4): 1 – 14.
- 118 [2] RC Moellering Jr. *Clin Infect Dis* 2014; 58: S1 – S3
- 119 [3] Kisgen JJ, Mansour H, Unger NR, Childs LM. Tedizolid: A new oxazolidinone antimicrobial
120 (Clinical Review). *Am J Health-Syst Pharm* 2014; 71: 621 – 33.
- 121 [4] Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical
122 studies of tedizolid to assess the potential for peripheral or central monoamine oxidase
123 interactions. *Antimicrob Agents Chemother.* 2013;57(7):3060-3066.

124

UNDER PEER REVIEW